What is Diabetes Therapeutics and Diagnostics Market?
Diabetes, scientifically known as diabetes mellitus, is a clinical condition in which a person has high blood sugar levels. It occurs due to the inefficiency of the pancreas in producing insulin (Type I) or the insensitivity of the body's cells to the insulin it produces (Type II), or both. Type II diabetes is common around the world due to increased obesity, urbanization, poor diet, and poor health conditions.
The market study is being classified by Type (Injectable [Insulin, Amylinomimetic] and Oral [Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl Peptidase IV Inhibitors]), by Application (Hospitals and Clinics) and major geographies with country level break-up.
Novartis Pharma AG (Switzerland), Owen Mumford Ltd. (United Kingdom), Palco Labs Inc. (United States), Novo Nordisk A/S (Denmark), Eli Lilly and Company (United States), Merck & Co. (United States), Abbott Laboratories (United States), Debiotech S.A. (Switzerland), Becton Dickinson (United States), Lifescan Inc. (United States), Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Inlight Solutions Inc. (United States), Terumo Corp. (Japan), Medtronic (Ireland), Animas Corp. (United States), Roche Holding AG (Switzerland) and Nipro Corp. (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Takeda Pharmaceutical Co. Ltd. (Japan), Agamatrix Inc. (Germany), Sanofi (France) and Ascensia (United States).
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Diabetes Therapeutics and Diagnostics market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Diabetes Therapeutics and Diagnostics market by Type, Application and Region.
On the basis of geography, the market of Diabetes Therapeutics and Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- The Growing Prevalence of Diabetes
- Growth in Sedentary Lifestyle of People
- Growing Older Population
- A Rise in Unhealthy Diet and Increasing Levels of Physical Inactivity
- High Incidences of Diabetes
- Robust Economic Growth, And Sweeping Healthcare Reforms
- An Increasing Prevalence of Common Health Disorders, Which Can Disable Patients and Potentially Lead To Fatal Health Complications
- Side Effects of Diabetic Drugs and Stringent Approval Process
- The Development of Affordable & Effective Diabetes Therapeutics
- Growth in Awareness among People about Self-Management of Diabetes and Support from the Government
- Lack of Awareness among Patients towards the Availability of Diabetic Medications
Key Target AudienceProviders of Diabetes Therapeutics and Diagnostics, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase